Skip to main content
Top
Published in: Annals of Surgical Oncology 13/2020

01-12-2020 | Pancreatectomy | ASO Author Reflections

ASO Author Reflections: From Concept to Real Clinical Practice of Laparoscopic Distal Pancreatectomy for Left-Sided Pancreatic Cancer

Author: Chang Moo Kang, MD, PhD

Published in: Annals of Surgical Oncology | Issue 13/2020

Login to get access

Excerpt

In spite of the potential clinical benefit of minimally invasive surgery, laparoscopic distal pancreatectomy (LDP) was contraindicated for left-sided pancreatic cancer. The pancreas is located in the retroperitoneal space, and there are important vascular structures near the pancreas, making the laparoscopic approach difficult. In addition, most left-sided pancreatic cancers are found in an advanced stage at diagnosis. Fears for incomplete radical surgery were widespread, which prevented intention-to-treat LDP for distal pancreatic cancer. However, with the advance of surgical techniques and experiences, efforts were carefully made to apply LDP for left-sided pancreatic cancer in selected patients. According to our institutional experience,1,2 bloodless and margin-negative resection were identified as independent prognostic factors in resected left-sided pancreatic cancer. Ideal tumor conditions were proposed (Yonsei criteria) as potential indicators for bloodless and margin-negative LPD for left-sided pancreatic cancer. …
Literature
1.
go back to reference Kang CM, Kim DH, Lee WJ. Ten years of experience with resection of left-sided pancreatic ductal adenocarcinoma: evolution and initial experience to a laparoscopic approach. Surg Endosc. 2010;24(7):1533–41.CrossRef Kang CM, Kim DH, Lee WJ. Ten years of experience with resection of left-sided pancreatic ductal adenocarcinoma: evolution and initial experience to a laparoscopic approach. Surg Endosc. 2010;24(7):1533–41.CrossRef
2.
go back to reference Kang CM, Lee SH, Lee WJ. Minimally invasive radical pancreatectomy for left-sided pancreatic cancer: current status and future perspectives. World J Gastroenterol. 2014;20(9):2343–51.CrossRef Kang CM, Lee SH, Lee WJ. Minimally invasive radical pancreatectomy for left-sided pancreatic cancer: current status and future perspectives. World J Gastroenterol. 2014;20(9):2343–51.CrossRef
3.
go back to reference Lee SH, Kang CM, Hwang HK, Choi SH, Lee WJ, Chi HS. Minimally invasive RAMPS in well-selected left-sided pancreatic cancer within Yonsei criteria: long-term (> median 3 years) oncologic outcomes. Surg Endosc. 2014;28(10):2848–55.CrossRef Lee SH, Kang CM, Hwang HK, Choi SH, Lee WJ, Chi HS. Minimally invasive RAMPS in well-selected left-sided pancreatic cancer within Yonsei criteria: long-term (> median 3 years) oncologic outcomes. Surg Endosc. 2014;28(10):2848–55.CrossRef
4.
go back to reference Lee SH, Hwang HK, Kang CM, Lee WJ. The Yonsei criteria as a clinically detectable parameter for excellent prognosis in resected left-sided pancreatic cancer: outcomes of a propensity score-matched analysis. Surg Endosc. 2017;31(11):4656–64.CrossRef Lee SH, Hwang HK, Kang CM, Lee WJ. The Yonsei criteria as a clinically detectable parameter for excellent prognosis in resected left-sided pancreatic cancer: outcomes of a propensity score-matched analysis. Surg Endosc. 2017;31(11):4656–64.CrossRef
5.
go back to reference de Rooij T, van Hilst J, van Santvoort H, et al. Minimally invasive versus open distal pancreatectomy (LEOPARD): a multicenter patient-blinded randomized controlled trial. Ann Surg. 2019;269(1):2–9.CrossRef de Rooij T, van Hilst J, van Santvoort H, et al. Minimally invasive versus open distal pancreatectomy (LEOPARD): a multicenter patient-blinded randomized controlled trial. Ann Surg. 2019;269(1):2–9.CrossRef
7.
go back to reference Strasberg SM, Drebin JA, Linehan D. Radical antegrade modular pancreatosplenectomy. Surgery. 2003;133(5):521–7.CrossRef Strasberg SM, Drebin JA, Linehan D. Radical antegrade modular pancreatosplenectomy. Surgery. 2003;133(5):521–7.CrossRef
8.
go back to reference Conroy T, Hammel P, Hebbar M, et al. FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer. N Engl J Med. 2018;379(25):2395–406.CrossRef Conroy T, Hammel P, Hebbar M, et al. FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer. N Engl J Med. 2018;379(25):2395–406.CrossRef
Metadata
Title
ASO Author Reflections: From Concept to Real Clinical Practice of Laparoscopic Distal Pancreatectomy for Left-Sided Pancreatic Cancer
Author
Chang Moo Kang, MD, PhD
Publication date
01-12-2020
Publisher
Springer International Publishing
Published in
Annals of Surgical Oncology / Issue 13/2020
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-020-08676-3

Other articles of this Issue 13/2020

Annals of Surgical Oncology 13/2020 Go to the issue